Innate Pharma Joins BTIG Virtual Biotechnology Conference

An announcement from Innate Pharma SA ( (FR:IPH) ) is now available.

Innate Pharma S.A. announced its participation in the BTIG Virtual Biotechnology Conference held on July 29-30, 2025. The company’s CEO and COO will engage in a fireside chat and one-on-one meetings, highlighting the company’s strategic engagement with financial services firm BTIG, which recently initiated analyst coverage of Innate Pharma. This participation underscores Innate Pharma’s efforts to strengthen its industry positioning and engage with stakeholders, potentially impacting its market visibility and investor relations.

The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes its proprietary ANKET® platform to create multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca to advance innovation in cancer treatment.

Average Trading Volume: 147,473

Technical Sentiment Signal: Sell

Current Market Cap: €175.9M

Learn more about IPH stock on TipRanks’ Stock Analysis page.